Avidity Partners Management
Latest statistics and disclosures from Avidity Partners Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ARVN, BSX, CI, TMO, ACHC, and represent 19.09% of Avidity Partners Management's stock portfolio.
- Added to shares of these 10 stocks: TMO (+$97M), CVS (+$58M), UTHR (+$52M), AVTR (+$48M), GPCR (+$48M), ABBV (+$44M), ALGN (+$43M), CI (+$43M), ACHC (+$34M), ISRG (+$29M).
- Started 10 new stock positions in A, ALGN, CVS, ABBV, Neurogene, IMNM, TMO, AVTR, ISRG, UTHR.
- Reduced shares in these 10 stocks: SRPT (-$55M), MLTX (-$44M), ZNTL (-$42M), IMVT (-$39M), JAZZ (-$38M), MCK (-$37M), DXCM (-$35M), , BDX (-$30M), UNH (-$28M).
- Sold out of its positions in ATEC, ALPN, ALT, BIIB, DXCM, GRTS, HCA, MLTX, NSTG, PACB. RYZB, SRPT, SDGR, UHS, VTYX, VERV, ZNTL, PRTA, ROIV, CVAC.
- Avidity Partners Management was a net seller of stock by $-113M.
- Avidity Partners Management has $2.7B in assets under management (AUM), dropping by 10.50%.
- Central Index Key (CIK): 0001791827
Tip: Access up to 7 years of quarterly data
Positions held by Avidity Partners Management consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Avidity Partners Management
Avidity Partners Management holds 73 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Arvinas Ord (ARVN) | 4.5 | $123M | +14% | 3.0M | 41.16 |
|
Boston Scientific Corporation (BSX) | 4.0 | $109M | -8% | 1.9M | 57.81 |
|
Cigna Corp Call Option (CI) | 3.8 | $105M | +68% | 350k | 299.45 |
|
Thermo Fisher Scientific (TMO) | 3.5 | $97M | NEW | 183k | 530.79 |
|
Acadia Healthcare (ACHC) | 3.3 | $90M | +61% | 1.2M | 77.76 |
|
Neurocrine Biosciences (NBIX) | 3.2 | $87M | 658k | 131.76 |
|
|
Syndax Pharmaceuticals (SNDX) | 3.1 | $85M | +40% | 4.0M | 21.61 |
|
Natera (NTRA) | 2.5 | $70M | +23% | 1.1M | 62.64 |
|
Structure Therapeutics Sponsored Ads (GPCR) | 2.5 | $69M | +236% | 1.7M | 40.76 |
|
Danaher Corporation (DHR) | 2.4 | $67M | +64% | 290k | 231.34 |
|
Tenet Healthcare Corp Com New (THC) | 2.4 | $66M | -9% | 871k | 75.57 |
|
Karuna Therapeutics Ord (KRTX) | 2.4 | $65M | -28% | 206k | 316.51 |
|
Fusion Pharmaceuticals (FUSN) | 2.3 | $63M | +12% | 6.5M | 9.61 |
|
Jazz Pharmaceuticals Shs Usd (JAZZ) | 2.2 | $60M | -38% | 489k | 123.00 |
|
Regeneron Pharmaceuticals (REGN) | 2.2 | $60M | +17% | 68k | 878.29 |
|
CVS Caremark Corporation (CVS) | 2.1 | $58M | NEW | 740k | 78.96 |
|
Blueprint Medicines (BPMC) | 2.1 | $57M | -18% | 615k | 92.24 |
|
ImmunoGen (IMGN) | 2.0 | $54M | -4% | 1.8M | 29.65 |
|
Ideaya Biosciences (IDYA) | 2.0 | $54M | -29% | 1.5M | 35.58 |
|
United Therapeutics Corporation (UTHR) | 1.9 | $52M | NEW | 237k | 219.89 |
|
Rocket Pharmaceuticals (RCKT) | 1.9 | $52M | +8% | 1.7M | 29.97 |
|
Intra Cellular Therapies (ITCI) | 1.9 | $51M | -11% | 710k | 71.62 |
|
Eli Lilly & Co. (LLY) | 1.8 | $50M | +13% | 85k | 582.92 |
|
Biohaven (BHVN) | 1.8 | $49M | -10% | 1.1M | 42.80 |
|
Avantor (AVTR) | 1.8 | $48M | NEW | 2.1M | 22.83 |
|
Zoetis Cl A (ZTS) | 1.7 | $47M | -8% | 240k | 197.37 |
|
Humana (HUM) | 1.7 | $46M | -9% | 100k | 457.81 |
|
Abbvie (ABBV) | 1.6 | $44M | NEW | 284k | 154.97 |
|
Align Technology (ALGN) | 1.6 | $43M | NEW | 156k | 274.00 |
|
Legend Biotech Corp Sponsored Ads (LEGN) | 1.5 | $41M | -29% | 685k | 60.17 |
|
Becton, Dickinson and (BDX) | 1.5 | $40M | -42% | 166k | 243.83 |
|
Ultragenyx Pharmaceutical (RARE) | 1.5 | $40M | +55% | 845k | 47.82 |
|
McKesson Corporation (MCK) | 1.4 | $40M | -48% | 86k | 462.98 |
|
Xenon Pharmaceuticals (XENE) | 1.4 | $38M | +153% | 816k | 46.06 |
|
Surgery Partners (SGRY) | 1.4 | $37M | -12% | 1.2M | 31.99 |
|
Axsome Therapeutics (AXSM) | 1.3 | $37M | +54% | 459k | 79.59 |
|
Caribou Biosciences (CRBU) | 1.3 | $36M | +5% | 6.4M | 5.73 |
|
Vaxcyte (PCVX) | 1.3 | $36M | -24% | 570k | 62.80 |
|
Neumora Therapeutics (NMRA) | 1.2 | $34M | +10% | 2.0M | 17.05 |
|
Mirum Pharmaceuticals (MIRM) | 1.2 | $34M | 1.1M | 29.52 |
|
|
UnitedHealth (UNH) | 1.1 | $31M | -47% | 59k | 526.47 |
|
Privia Health Group (PRVA) | 1.1 | $30M | -16% | 1.3M | 23.03 |
|
Intuitive Surgical Com New (ISRG) | 1.0 | $29M | NEW | 85k | 337.36 |
|
Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 0.9 | $24M | -31% | 380k | 62.00 |
|
An2 Therapeutics (ANTX) | 0.9 | $23M | +4% | 1.1M | 20.49 |
|
Ac Immune Sa SHS (ACIU) | 0.8 | $22M | +50% | 4.5M | 5.00 |
|
Arrowhead Pharmaceuticals (ARWR) | 0.8 | $22M | -32% | 714k | 30.60 |
|
Immunocore Hldgs Ads (IMCR) | 0.7 | $21M | -13% | 300k | 68.32 |
|
Crinetics Pharmaceuticals In (CRNX) | 0.7 | $19M | -13% | 529k | 35.58 |
|
Phathom Pharmaceuticals (PHAT) | 0.6 | $16M | +6% | 1.7M | 9.13 |
|
Verona Pharma Sponsored Ads (VRNA) | 0.6 | $16M | -5% | 781k | 19.88 |
|
Immunome (IMNM) | 0.5 | $14M | NEW | 1.3M | 10.70 |
|
Agilent Technologies Inc C ommon (A) | 0.5 | $14M | NEW | 99k | 139.03 |
|
Intellia Therapeutics (NTLA) | 0.5 | $14M | +18% | 447k | 30.49 |
|
Syros Pharmaceuticals Com New (SYRS) | 0.5 | $13M | +5% | 1.7M | 7.79 |
|
Dianthus Therapeutics (DNTH) | 0.5 | $13M | 1.2M | 10.40 |
|
|
Argenx Se Sponsored Adr (ARGX) | 0.4 | $12M | -61% | 31k | 380.43 |
|
Cerevel Therapeutics Hldng I (CERE) | 0.4 | $12M | -56% | 277k | 42.40 |
|
Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 0.4 | $11M | +3% | 361k | 30.78 |
|
Immunovant (IMVT) | 0.4 | $10M | -79% | 245k | 42.13 |
|
Neurogene | 0.3 | $9.0M | NEW | 466k | 19.38 |
|
Travere Therapeutics (TVTX) | 0.3 | $7.4M | -37% | 827k | 8.99 |
|
Karyopharm Therapeutics (KPTI) | 0.3 | $7.2M | 8.3M | 0.86 |
|
|
Akero Therapeutics (AKRO) | 0.2 | $5.5M | -68% | 235k | 23.35 |
|
Kezar Life Sciences (KZR) | 0.2 | $4.8M | -16% | 5.0M | 0.95 |
|
Century Therapeutics (IPSC) | 0.2 | $4.5M | +23% | 1.4M | 3.32 |
|
Scynexis Com New (SCYX) | 0.1 | $3.2M | +9% | 1.4M | 2.23 |
|
Compass Therapeutics (CMPX) | 0.1 | $2.5M | 1.6M | 1.56 |
|
|
Revolution Medicines (RVMD) | 0.1 | $1.7M | -90% | 60k | 28.68 |
|
Hyperfine Com Cl A (HYPR) | 0.0 | $1.3M | 1.2M | 1.12 |
|
|
Amylyx Pharmaceuticals (AMLX) | 0.0 | $950k | -96% | 65k | 14.72 |
|
Caremax Com Cl A (CMAX) | 0.0 | $317k | 636k | 0.50 |
|
|
Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $5.4k | 90k | 0.06 |
|
Past Filings by Avidity Partners Management
SEC 13F filings are viewable for Avidity Partners Management going back to 2019
- Avidity Partners Management 2023 Q4 filed Feb. 14, 2024
- Avidity Partners Management 2023 Q3 filed Nov. 14, 2023
- Avidity Partners Management 2023 Q2 filed Aug. 14, 2023
- Avidity Partners Management 2023 Q1 filed May 15, 2023
- Avidity Partners Management 2022 Q4 filed Feb. 14, 2023
- Avidity Partners Management 2022 Q3 filed Nov. 14, 2022
- Avidity Partners Management 2022 Q2 filed Aug. 15, 2022
- Avidity Partners Management 2022 Q1 filed May 16, 2022
- Avidity Partners Management 2021 Q4 filed Feb. 14, 2022
- Avidity Partners Management 2021 Q3 filed Nov. 15, 2021
- Avidity Partners Management 2021 Q2 filed Aug. 16, 2021
- Avidity Partners Management 2021 Q1 filed May 17, 2021
- Avidity Partners Management 2020 Q4 filed Feb. 16, 2021
- Avidity Partners Management 2020 Q3 filed Nov. 16, 2020
- Avidity Partners Management 2020 Q2 filed Aug. 14, 2020
- Avidity Partners Management 2019 Q4 amended filed June 17, 2020